Clinical analysis of the influence of bevacizumab on the recrudescence of the limbal corneal epithelial cell auto-graft transplantation in treating patients with pterygium / 中国基层医药

ABSTRACT

Objective To explore the clinical effents of bevacizumab on the recrudescence of the limbal corneal epithelial cell auto-graft transplantation in treating patients with pterygium.Methods The clinical data of 75 cases(99 eyes) with pterygium were retraspectively reviewed,and they were divided into 3 groups by different conservative treatment.A groupthe limbal corneal epithelial cell auto-graft transplantation combined with bevacizumab.B groupthe limbal corneal epithelial cell auto-graft transplantation combined with MMC.C groupthe limbal corneal epithelial cell auto-graft transplantation.After follow-up for 3 months,the curative effect and recurrence were compared between the two groups.Results The recurrence of three groups was significantly different( x2 =12.267,P ＜ 0.05 ).The reccurrence rate of A,B,C group were 12.1％,15.2％,45.5％.The recurrence rate of A group and B group wasn't significantly different(x2 =2.117,P ＞0.05).The recurrence rate of B group and C group wasn't statistically different( x2 --3.930,P ＜ 0.05 ).The recurrence rate of A group and C group was significantly different( x2 =4.155,P ＜ 0.05 ).After 1 week,all patients had different degrees of eye pain,photophobia or tearing,and disappeared after 1 week;2 patients in group B found that limbal shallow scleral necrosis,superficial punctate keratitis.The average time of removal of stitches in group A was 5.9d,group B was 7.0d and group C was 7.5d.Conclusion Bevacizumab could obviously reduce the recrudescence of the limbal corneal epithelial cell auto-graft transplantation in treating patients with pterygium.It was safe with less complications and good prognosis.It was worthy for being widely used in treatment of pterygium.